Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL- positive acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL- positive acute lymphoblastic leukemia

Published:2017-02-21 Issue:4 Volume:92 Page:367-374
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Fujisawa Shin¹^ORCID,Mizuta Shuichi²,Akiyama Hideki³,Ueda Yasunori⁴,Aoyama Yasutaka⁵,Hatta Yoshihiro⁶,Kakihana Kazuhiko⁷,Dobashi Nobuaki⁸,Sugiura Isamu⁹,Onishi Yasushi¹⁰,Maeda Tomoya¹¹,Imai Kiyotoshi¹²,Ohtake Shigeki¹³,Miyazaki Yasushi¹⁴,Ohnishi Kazunori¹⁵,Matsuo Keitaro¹⁶,Naoe Tomoki¹⁷

Affiliation:

1. Department of Hematology; Yokohama City University Medical Center; Yokohama Japan

2. Department of Hematology; Fujita Health University Hospital; Toyoake Japan

3. Tokyo Metropolitan Health and Medical Treatment Corporation Tama-Hokubu Medical Center; Tokyo Japan

4. Department of Hematology/Oncology; Kurashiki Central Hospital; Kurashiki Japan

5. Department of Hematology; Seichokai Fuchu Hospital; Osaka Japan

6. Department of Hematology and Rheumatology; Nihon University School of Medicine; Tokyo Japan

7. Hematology Division; Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Tokyo Japan

8. Division of Clinical Oncology and Hematology; Department of Internal Medicine, The Jikei University School of Medicine; Tokyo Japan

9. Division of Hematology and Oncology; Toyohashi Municipal Hospital; Toyohashi Japan

10. Department of Hematology and Rheumatology; Tohoku University Hospital; Sendai Japan

11. Department of Hemato-Oncology; Saitama Medical University International Medical Center; Hidaka Japan

12. Department of Hematology; Sapporo Hokuyu Hospital; Sapporo Japan

13. Institute of Liberal Arts and Science, Kanazawa University; Kanazawa Japan

14. Department of Hematology; Atomic Bomb Disease Institute, Nagasaki University; Nagasaki Japan

15. Oncology Center, Hamamatsu University School of Medicine; Hamamatsu Japan

16. Division of Molecular Medicine, Aichi Cancer Center Research Institute; Nagoya Japan

17. National Hospital Organization Nagoya Medical Center; Nagoya Japan

Funder

Society of the Friendly Sons of St. Patrick for the Relief of Emigrants from Ireland

Publisher

Wiley

Subject

Hematology

Reference21 articles.

1. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial;Moorman;Blood.,2007

2. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study;Takeuchi;Leukemia.,2002

3. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993;Fielding;Blood.,2009

4. Japan Adult Leukemia Study Group. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy;Yanada;Br J Haematol.,2008

5. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia;Mizuta;Leukemia.,2011

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL);Current Treatment Options in Oncology;2024-08-05

2. A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens;Hematology;2024-04-06

3. Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission;American Journal of Hematology;2024-02-05

4. High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT Study;HemaSphere;2023-06

5. IKZF1^plus alterations are not associated with outcomes in Philadelphia‐positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL/MRD2008 trial;European Journal of Haematology;2023-04-08